{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,26]],"date-time":"2025-10-26T14:39:18Z","timestamp":1761489558812},"reference-count":20,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2015,2,5]],"date-time":"2015-02-05T00:00:00Z","timestamp":1423094400000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Med"],"published-print":{"date-parts":[[2015,12]]},"DOI":"10.1186\/s12916-015-0270-2","type":"journal-article","created":{"date-parts":[[2015,2,4]],"date-time":"2015-02-04T13:24:29Z","timestamp":1423056269000},"update-policy":"http:\/\/dx.doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":4,"title":["Why are there deadly drugs?"],"prefix":"10.1186","volume":"13","author":[{"given":"Joel","family":"Lexchin","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2015,2,5]]},"reference":[{"key":"270_CR1","doi-asserted-by":"crossref","unstructured":"Onakpoya I, Heneghan C, Aronson J. Delays in the post-marketing withdrawal of drugs to which deaths have been attributed: a systematic investigation and analysis. BMC Medicine 2015.","DOI":"10.1186\/s12916-014-0262-7"},{"key":"270_CR2","doi-asserted-by":"publisher","first-page":"1728","DOI":"10.1001\/jama.281.18.1728","volume":"281","author":"M Friedman","year":"1999","unstructured":"Friedman M, Woodcock J, Lumpkin M, Shuren J, Hass A, Thompson L. The safety of newly approved medicines: do recent market removals mean there is a problem? JAMA. 1999;281:1728\u201334.","journal-title":"JAMA"},{"key":"270_CR3","volume-title":"The world medicines situation report","author":"World Health Organization","year":"2004","unstructured":"World Health Organization. The world medicines situation report. Geneva: WHO; 2004."},{"key":"270_CR4","volume-title":"The world medicines situation 2011: pharmacovigilance and safety of medicines","author":"S Pal","year":"2011","unstructured":"Pal S, Dodoo A, Mantel A, Olsson S. The world medicines situation 2011: pharmacovigilance and safety of medicines. Geneva: WHO; 2011."},{"key":"270_CR5","doi-asserted-by":"crossref","unstructured":"Kamal-Yanni M, Saunders P. Urgent need for WHO\u2019s reform to prioritise core functions. Lancet. 2012;379:1878.","DOI":"10.1016\/S0140-6736(12)60810-1"},{"key":"270_CR6","doi-asserted-by":"publisher","first-page":"1261","DOI":"10.1016\/S0140-6736(05)67518-6","volume":"366","author":"P Lurie","year":"2005","unstructured":"Lurie P, Wofle SM. Misleading data analyses in salmeterol (SMART) study. Lancet. 2005;366:1261\u20132.","journal-title":"Lancet"},{"key":"270_CR7","doi-asserted-by":"publisher","first-page":"1813","DOI":"10.1001\/jama.299.15.1813","volume":"299","author":"BM Psaty","year":"2008","unstructured":"Psaty BM, Kronmal RA. Reporting mortality findings in trials of rofecoxib for Alzheimer disease or cognitive impairment: a case study based on documents from rofecoxib litigation. JAMA. 2008;299:1813\u20137.","journal-title":"JAMA"},{"key":"270_CR8","doi-asserted-by":"publisher","first-page":"1985","DOI":"10.1001\/archinternmed.2009.399","volume":"169","author":"S Woloshin","year":"2009","unstructured":"Woloshin S, Schwartz L. Bringing the FDA\u2019s information to market. Arch Intern Med. 2009;169:1985\u20137.","journal-title":"Arch Intern Med"},{"key":"270_CR9","doi-asserted-by":"crossref","unstructured":"Habibi R, Lexchin J. Quality and quantity of information in summary basis of decision documents issued by health Canada. PLoS One. 2014;9:e92038.","DOI":"10.1371\/journal.pone.0092038"},{"key":"270_CR10","doi-asserted-by":"crossref","unstructured":"Barbui C, Baschirotto C, Cipriani A. EMA must improve the quality of its clinical trial reports. BMJ. 2011;342:d2291.","DOI":"10.1136\/bmj.d2291"},{"key":"270_CR11","doi-asserted-by":"publisher","first-page":"1354","DOI":"10.1056\/NEJMsa0706341","volume":"358","author":"D Carpenter","year":"2008","unstructured":"Carpenter D, Zucker E, Avorn J. Drug-review deadlines and safety problems. New Engl J Med. 2008;358:1354\u201361.","journal-title":"New Engl J Med"},{"key":"270_CR12","doi-asserted-by":"publisher","first-page":"1680","DOI":"10.1001\/archinternmed.2012.4444","volume":"172","author":"J Lexchin","year":"2012","unstructured":"Lexchin J. New drugs and safety: what happened to new active substances approved in Canada between 1995 and 2010? Arch Intern Med. 2012;172:1680\u20131.","journal-title":"Arch Intern Med"},{"key":"270_CR13","doi-asserted-by":"publisher","first-page":"1756","DOI":"10.1001\/archinternmed.2009.306","volume":"169","author":"I Pitrou","year":"2009","unstructured":"Pitrou I, Boutron I, Ahmad N, Ravaud P. Reporting of safety results in published reports of randomized controlled trials. Arch Intern Med. 2009;169:1756\u201361.","journal-title":"Arch Intern Med"},{"key":"270_CR14","doi-asserted-by":"publisher","first-page":"1693","DOI":"10.1016\/j.juro.2010.01.030","volume":"183","author":"R Breau","year":"2010","unstructured":"Breau R, Gaboury I, Scales C, Fesperman S, Watterson J, Dahm P. Reporting of harm in randomized controlled trials published in the urological literature. J Urol. 2010;183:1693\u20137.","journal-title":"J Urol"},{"key":"270_CR15","doi-asserted-by":"publisher","first-page":"385","DOI":"10.2165\/00002018-200629050-00003","volume":"29","author":"L Hazell","year":"2006","unstructured":"Hazell L, Shakir S. Under-reporting of adverse drug reactions: a systematic review. Drug Saf. 2006;29:385\u201396.","journal-title":"Drug Saf"},{"key":"270_CR16","doi-asserted-by":"publisher","first-page":"477","DOI":"10.2165\/00002018-200427070-00004","volume":"27","author":"N Mittmann","year":"2004","unstructured":"Mittmann N, Knowles S, Gomez M, Fish J, Cartotto R, Shear N. Evaluation of the extent of under-reporting of serious adverse drug reactions: the case of toxic epidermal necrolysis. Drug Saf. 2004;27:477\u201387.","journal-title":"Drug Saf"},{"key":"270_CR17","doi-asserted-by":"publisher","first-page":"1752","DOI":"10.1001\/archinte.167.16.1752","volume":"167","author":"T Moore","year":"2007","unstructured":"Moore T, Cohen M, Furberg C. Serious adverse drug events reported to the Food and Drug Administration, 1998\u20132005. Arch Intern Med. 2007;167:1752\u20139.","journal-title":"Arch Intern Med"},{"key":"270_CR18","volume-title":"Dispensing with the truth: the victims, the drug companies, and the dramatic story behind the battle over fen-phen","author":"A Mundy","year":"2001","unstructured":"Mundy A. Dispensing with the truth: the victims, the drug companies, and the dramatic story behind the battle over fen-phen. New York: St. Martin\u2019s Press; 2001."},{"key":"270_CR19","volume-title":"Keeping an eye on prescription drugs, keeping Canadians safe: active monitoring systems for drug safety and effectiveness in Canada and internationally","author":"M Wiktorowicz","year":"2010","unstructured":"Wiktorowicz M, Lexchin J, Moscou K, Silversides A, Eggertson L. Keeping an eye on prescription drugs, keeping Canadians safe: active monitoring systems for drug safety and effectiveness in Canada and internationally. Toronto: Health Council of Canada; 2010."},{"key":"270_CR20","volume-title":"Reputation and power: organizational image and pharmaceutical regulation at the FDA","author":"D Carpenter","year":"2010","unstructured":"Carpenter D. Reputation and power: organizational image and pharmaceutical regulation at the FDA. Princeton University Press: Princeton; 2010."}],"container-title":["BMC Medicine"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/article\/10.1186\/s12916-015-0270-2\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s12916-015-0270-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s12916-015-0270-2","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s12916-015-0270-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,2,26]],"date-time":"2019-02-26T12:39:21Z","timestamp":1551184761000},"score":1,"resource":{"primary":{"URL":"http:\/\/bmcmedicine.biomedcentral.com\/articles\/10.1186\/s12916-015-0270-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015,2,5]]},"references-count":20,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2015,12]]}},"alternative-id":["270"],"URL":"https:\/\/doi.org\/10.1186\/s12916-015-0270-2","relation":{},"ISSN":["1741-7015"],"issn-type":[{"value":"1741-7015","type":"electronic"}],"subject":[],"published":{"date-parts":[[2015,2,5]]},"article-number":"27"}}